clinical trial · NCT07101094
Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)
Bristol-Myers Squibb·—·recruiting·n = 300
Schizophreniaxanomeline and trospium chloride (X/T) therapy
brief summary
The purpose of this study is to understand treatment preference and satisfaction among adults with schizophrenia in the United States who are prescribed xanomeline and trospium chloride (X/T) therapy
started
Sep 22, 2025
primary completion
Jan 31, 2029
completion
May 14, 2029
last updated
Jun 18, 2026
official title
Real-world Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol